Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Elife. 2019 Aug 8;8:e47313. doi: 10.7554/eLife.47313.
Hepatocytes are regarded as the only effective cell source for cell transplantation to treat liver diseases; however, their availability is limited due to a donor shortage. Thus, a novel cell source must be developed. We recently reported that mature rodent hepatocytes can be reprogrammed into progenitor-like cells with a repopulative capacity using small molecule inhibitors. Here, we demonstrate that hepatic progenitor cells can be obtained from human infant hepatocytes using the same strategy. These cells, named human chemically induced liver progenitors (hCLiPs), had a significant repopulative capacity in injured mouse livers following transplantation. hCLiPs redifferentiated into mature hepatocytes in vitro upon treatment with hepatic maturation-inducing factors. These redifferentiated cells exhibited cytochrome P450 (CYP) enzymatic activities in response to CYP-inducing molecules and these activities were comparable with those in primary human hepatocytes. These findings will facilitate liver cell transplantation therapy and drug discovery studies.
肝细胞被认为是细胞移植治疗肝脏疾病的唯一有效细胞来源;然而,由于供体短缺,其可用性有限。因此,必须开发新的细胞来源。我们最近报道,使用小分子抑制剂可以将成熟的啮齿动物肝细胞重编程为具有再生能力的祖细胞样细胞。在这里,我们证明使用相同的策略可以从人胎肝细胞中获得肝祖细胞。这些细胞被命名为人化学诱导的肝祖细胞(hCLiPs),在移植后可显著重建受损小鼠肝脏。hCLiPs 在体外用肝成熟诱导因子处理后可重新分化为成熟肝细胞。这些再分化的细胞对 CYP 诱导分子表现出细胞色素 P450(CYP)酶活性,并且这些活性与原代人肝细胞相当。这些发现将促进肝细胞移植治疗和药物发现研究。